Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Thomas Haimowitz"'
Autor:
Srinivas K. Chunduru, Mark A. McKinlay, Yigong Shi, David Weng, Martin A. Graham, Matthew D. Alexander, Thomas Haimowitz, Yu-Hua Lee, Pavan K. Tirunahari, Mukta S. Hendi, Yijun Deng, Susan R. Rippin, Matthew G. LaPorte, Gurpreet S. Kapoor, Martin E. Seipel, Guangyao Yu, Stephen M. Condon, Eric M. Neiman, Jennifer M. Burns, Yasuhiro Mitsuuchi, Christopher A. Benetatos
The acquisition of apoptosis resistance is a fundamental event in cancer development. Among the mechanisms used by cancer cells to evade apoptosis is the dysregulation of inhibitor of apoptosis (IAP) proteins. The activity of the IAPs is regulated by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::749eac6e33c3d6ae4c15d5416ec41d41
https://doi.org/10.1158/1535-7163.c.6536442.v1
https://doi.org/10.1158/1535-7163.c.6536442.v1
Autor:
Srinivas K. Chunduru, Mark A. McKinlay, Yigong Shi, David Weng, Martin A. Graham, Matthew D. Alexander, Thomas Haimowitz, Yu-Hua Lee, Pavan K. Tirunahari, Mukta S. Hendi, Yijun Deng, Susan R. Rippin, Matthew G. LaPorte, Gurpreet S. Kapoor, Martin E. Seipel, Guangyao Yu, Stephen M. Condon, Eric M. Neiman, Jennifer M. Burns, Yasuhiro Mitsuuchi, Christopher A. Benetatos
PDF file - 1384KB, Supplemental Figure 1. Structure of biotinylated birinapant Supplemental Figure 2. Concentration-dependent degradation of GFP-cIAP1/2 by birinapant Supplemental Figure 3. Representative examples of data analysis from 111 cell line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77cfd31d3e0c71e37181fc6d9362974f
https://doi.org/10.1158/1535-7163.22500405.v1
https://doi.org/10.1158/1535-7163.22500405.v1
Autor:
Srinivas K. Chunduru, Mark A. McKinlay, Yigong Shi, David Weng, Martin A. Graham, Matthew D. Alexander, Thomas Haimowitz, Yu-Hua Lee, Pavan K. Tirunahari, Mukta S. Hendi, Yijun Deng, Susan R. Rippin, Matthew G. LaPorte, Gurpreet S. Kapoor, Martin E. Seipel, Guangyao Yu, Stephen M. Condon, Eric M. Neiman, Jennifer M. Burns, Yasuhiro Mitsuuchi, Christopher A. Benetatos
PDF file - 73KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6017e6fd5bb940ccaf18ea18c0384148
https://doi.org/10.1158/1535-7163.22500408.v1
https://doi.org/10.1158/1535-7163.22500408.v1
Autor:
Srinivas K. Chunduru, Mark A. McKinlay, Yigong Shi, David Weng, Martin A. Graham, Matthew D. Alexander, Thomas Haimowitz, Yu-Hua Lee, Pavan K. Tirunahari, Mukta S. Hendi, Yijun Deng, Susan R. Rippin, Matthew G. LaPorte, Gurpreet S. Kapoor, Martin E. Seipel, Guangyao Yu, Stephen M. Condon, Eric M. Neiman, Jennifer M. Burns, Yasuhiro Mitsuuchi, Christopher A. Benetatos
XLS file - 45KB, Sensitivity of a 111 cell line panel to birinapant as a single agent and in combination with TNF or TRAIL.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77a5608cfd12aa98c693523b28ad5a19
https://doi.org/10.1158/1535-7163.22500402.v1
https://doi.org/10.1158/1535-7163.22500402.v1
Autor:
Xufeng Sun, Parveen Akhtar, Christina Ng DiMarco, Dennis Arefyev, Yijun Deng, Tanya Vakhilt, Ramachandar Tokala, Jaclyn White, Lei Zhu, Marco Jonas, Stephen M. Condon, Thomas Haimowitz
Publikováno v:
Organic Process Research & Development. 20:1812-1820
SHP-141 (1) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes which is under development for the treatment of cutaneous T-cell lymphoma. The original synthesis of 1 involved five synthetic steps beginning with suberic acid monomethy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df78273bb84e11f9dce04f31e1cdac19
https://doi.org/10.1021/acs.oprd.6b00280
https://doi.org/10.1021/acs.oprd.6b00280
Autor:
Debasis Patra, Matthew D Alexander, Yijun Deng, Robert S. Antonovich, Yu-Hua Lee, Qiuzhe Xie, Mark A. Mortensen, Stephen M. Condon, Pavan Tirunahari Kumar, Arthur J. Cooper, Matthew G. LaPorte, Jun Yan, Hong Cao, Mukta S. Hendi, Chasnoff Anna, Susan R. Rippin, Thomas Haimowitz, Seth A. Putrelo
Publikováno v:
Organic Process Research & Development. 20:242-252
Birinapant/TL32711 (1) is a novel bivalent antagonist of the inhibitor of apoptosis (IAP) family of proteins which is currently in clinical development for the treatment of cancer and hepatitis B virus (HBV) infection. In this report, we present a de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4e3b5f11c51cf700a1fabceed5c4aea
https://doi.org/10.1021/acs.oprd.5b00390
https://doi.org/10.1021/acs.oprd.5b00390
Autor:
Yu-Hua Lee, Stephen M. Condon, Pavan Tirunahari Kumar, Mukta S. Hendi, Yijun Deng, Matthew D Alexander, Susan R. Rippin, Matthew G. LaPorte, Thomas Haimowitz
Publikováno v:
ACS Medicinal Chemistry Letters. 7:318-323
Birinapant/TL32711 (1) is a bivalent antagonist of the inhibitor of apoptosis (IAP) family of proteins and was designed to mimic AVPI, the N-terminal tetrapeptide of the second mitochondria-derived activator of caspases (Smac/DIABLO). Birinapant boun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d58c8b59cae1b20c616fcfc33a12d44
https://doi.org/10.1021/acsmedchemlett.5b00461
https://doi.org/10.1021/acsmedchemlett.5b00461
Publikováno v:
Tetrahedron Letters. 43:7101-7104
Addition of carbon nucleophiles to 2-acetamido-2-deoxygluconolactones fails for many reagents, but trialkylaluminums add alkyl smoothly. The product of methyl addition to 2-acetamido-2-deoxy- d -gluconolactone has been converted to 1- C -methyl GlcNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81ed9e3c13e9682438eb40b34efdd33c
https://doi.org/10.1016/s0040-4039(02)01506-x
https://doi.org/10.1016/s0040-4039(02)01506-x
Autor:
Stephen M. Condon, Pavan Tirunahari Kumar, Eric M. Neiman, Yijun Deng, Thomas Haimowitz, Bodhi Bettjeman, Yu Hua Lee, Xiaochun Li, Gurpreet S. Kapoor, Mukta S. Hendi, Rebecca Feltham, Martin E. Seipel, Christopher A. Benetatos, Jiawei Wang, Guangyao Yu, Catherine L. Day, James E Vince, Matthew D Alexander, Susan R. Rippin, Jennifer M. Burns, John Silke, Matthew G. LaPorte, Yasuhiro Mitsuuchi, Nufail Khan, Yigong Shi, Mark A. McKinlay, Mathew H. Cumming, Martin A. Graham, Srinivas K. Chunduru
Publikováno v:
Journal of medicinal chemistry. 57(9)
Birinapant (1) is a second-generation bivalent antagonist of IAP proteins that is currently undergoing clinical development for the treatment of cancer. Using a range of assays that evaluated cIAP1 stability and oligomeric state, we demonstrated that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e0ccaed261bf6a4bdf8dd9b2b39afe3
https://pubmed.ncbi.nlm.nih.gov/24684347
https://pubmed.ncbi.nlm.nih.gov/24684347
Autor:
Christopher A. Benetatos, Martin E. Seipel, Pavan K. Tirunahari, Yu-Hua Lee, Thomas Haimowitz, Yijun Deng, Gurpreet S. Kapoor, Matthew D Alexander, Martin A. Graham, Srinivas K. Chunduru, Mukta S. Hendi, Eric M. Neiman, Jennifer M. Burns, Guangyao Yu, Stephen M. Condon, David E. Weng, Yasuhiro Mitsuuchi, Mark A. McKinlay, Susan R. Rippin, Matthew G. LaPorte, Yigong Shi
Publikováno v:
Molecular cancer therapeutics. 13(4)
The acquisition of apoptosis resistance is a fundamental event in cancer development. Among the mechanisms used by cancer cells to evade apoptosis is the dysregulation of inhibitor of apoptosis (IAP) proteins. The activity of the IAPs is regulated by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d2b571ef4e2a2d53e334bf1139039ea
https://pubmed.ncbi.nlm.nih.gov/24563541
https://pubmed.ncbi.nlm.nih.gov/24563541